|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 29, 2012 ) New York, NY -- On August 13th, shares of Synergy Pharmaceuticals (SGYP) hit an intra-day low of $3.66 before closing the day at $3.74. Now, just two weeks later, shares routinely trade for a buck higher while volume has modestly increased, too. The quick price spike in itself could certainly attract the attention of investors looking for a nice momentum play or trading opportunity, but the company has enough pending catalysts and developing stories in play to justify the recent price increases, and potentially more.
VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, believes that Synergy shares could move much higher, should the late-year trial catalyst pan out for the positive. For a more in-depth look at recent SGYP catalysts visit: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-moving-on-recent-merger-and-acquisition-deals
Synergy had initially moved higher during the dog days of summer after a merger with Callisto Pharmaceuticals (CLSP) was announced in late July. The merger put Synergy in a position of strength in its quest to attract a more committed investor because - as a result of the deal - Callisto's previously-held for percent stake in SGYP will be cancelled and distributed evenly amongst Callisto investors. Many large funds and institutions are hesitant to buy into a company already forty percent owned by another entity. The merger agreement alleviated this roadblock.
Synergy then followed up the Callisto news with a confirmation that a much-anticipated, end-of-year trial milestone was still on track. Results from the recently-closed Plecanatide Phase IIb/III trial should be out by the closing weeks of December and investors could then better gauge the company's true potential moving forward. It is expected that these results will be positive, considering Plecanatide's shared origins and same mechanism of action as Ironwood Pharmaceuticals' (IRWD) Linaclotide, which is currently before the FDA for approval review with a decision due within weeks.
While these catalysts provided fuel for SGYP's recent price spike, the company announced yet another significant development last week - one that caught many investors by surprise. It was announced last week that an Asset Purchase Agreement with Bristol-Myers Squibb Company (BMY) had taken place and would add FV-100 for the treatment for shingles, to Synergy's pipeline. The FV-100 deal diversifies the company's portfolio and right off the bat does three things for the company - boosts the overall value and potential of Synergy Pharmaceuticals in the event of a buyout; provides a backup pipeline in case the lead candidate does not make it through approval, and legitimizes the company in its quest to become a much bigger player in the sector. The full financial terms of the deal were not disclosed but it was revealed that Synergy paid an up-front sum of $1 million. SGYP shares spiked by five percent on the news.
The Callisto deal also brought a few more pipeline products into the fold to team with Plecanatide and now FV-100, including the Phase II cancer treatment Atiprimod, the Phase I L-Annamycin and the pre-clinical Degrasyns.
Neither of the acquisition/merger deals were earth-shattering news, but even before any of it hit the wires, some analysts had already tagged SGYP with price targets at least double the current levels. Such valuations are based on the potential of the company's flagship product, Plecanatide, on the open market in the treatment of chronic idiopathic constipation (CIC) - and eventually also constipation-predominant irritable bowel syndrome (IBS-C) - and did not take into account the new pipeline boost.
In regards to Synergy's main product candidate, Plecanatide, investors may have cause for concern with the fact that it is further behind in development than Linaclotide - which is slated to receive an FDA approval decision for the same indications within weeks - but a more favorable side effect profile for Plecanatide has analysts and investors convinced that any initial momentum gained by Linaclotide on the open market could be quickly recaptured by Plecanatide, should it also muster an eventual FDA approval. When the Phase IIb/III results hit later this year, investors will have much more of a clue as to just how valid the recent price targets are and whether the previously-discussed potential is real.
Follow SGYP developments at VFCsStockHouse.com
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
